Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Pandion Therapeutics Inc (PAND)

Pandion Therapeutics Inc (PAND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,772,436
  • Shares Outstanding, K 29,516
  • Annual Sales, $ 8,780 K
  • Annual Income, $ -38,110 K
  • 60-Month Beta N/A
  • Price/Sales 201.89
  • Price/Cash Flow N/A
  • Price/Book 8.26
Trade PAND with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -10.66
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 04/05/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.37
  • Number of Estimates 1
  • High Estimate -0.37
  • Low Estimate -0.37
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
59.60 +0.76%
on 03/04/21
62.90 -4.53%
on 03/02/21
-0.15 (-0.25%)
since 02/26/21
3-Month
14.55 +312.71%
on 12/31/20
62.90 -4.53%
on 03/02/21
+44.94 (+297.42%)
since 12/28/20

Most Recent Stories

More News
Merck Completes Acquisition of Pandion Therapeutics

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common...

MRK : 108.84 (+0.36%)
PAND : 60.05 (+0.22%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates CTB, FFG, PAND, SVBI; Shareholders Are Encouraged to Contact the Firm

NEW YORK, March 23, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

CTB : 60.17 (-0.05%)
FFG : 60.99 (+0.03%)
PAND : 60.05 (+0.22%)
SVBI : 13.63 (+5.66%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates WIFI, PRAH, PAND, CTB; Shareholders Are Encouraged to Contact the Firm

NEW YORK, March 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

WIFI : 13.99 (+0.07%)
PRAH : 165.21 (-1.67%)
PAND : 60.05 (+0.22%)
CTB : 60.17 (-0.05%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Buyout Investigation

WILMINGTON, Del., March 04, 2021 (GLOBE NEWSWIRE) --

PAND : 60.05 (+0.22%)
PRAH : 165.21 (-1.67%)
TPCO : 17.26 (+0.41%)
Merck Begins Tender Offer to Acquire Pandion Therapeutics

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Pandion Therapeutics,...

MRK : 108.84 (+0.36%)
PAND : 60.05 (+0.22%)
PANDION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pandion Therapeutics, Inc. - PAND

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pandion Therapeutics, Inc. (NasdaqGS: PAND)...

PAND : 60.05 (+0.22%)
MRK : 108.84 (+0.36%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates PAND, PRAH, FFG, CTB; Shareholders Are Encouraged to Contact the Firm

NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

PAND : 60.05 (+0.22%)
PRAH : 165.21 (-1.67%)
FFG : 60.99 (+0.03%)
CTB : 60.17 (-0.05%)
Moore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law Firm

NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...

PAND : 60.05 (+0.22%)
SFTW : 11.41 (+9.71%)
PRAH : 165.21 (-1.67%)
RTP : 10.03 (-4.48%)
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Pandion Therapeutics, Inc. Buyout

WILMINGTON, Del., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Pandion Therapeutics, Inc. (“Pandion”) (NASDAQ GS: PAND ) regarding possible breaches...

PAND : 60.05 (+0.22%)
MRK : 108.84 (+0.36%)
PANDION ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PAND and Encourages Investors to Contact the Firm

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Pandion Therapeutics,...

PAND : 60.05 (+0.22%)
MRK : 108.84 (+0.36%)

Business Summary

Pandion Therapeutics Inc. is a biotechnology company. It focuses on developing modular proteins, antibodies and bispecifics for the treatment of autoimmune and inflammatory diseases. Pandion Therapeutics Inc. is based in North Cambridge, United States.

See More

Key Turning Points

3rd Resistance Point 60.18
2nd Resistance Point 60.12
1st Resistance Point 60.08
Last Price 60.05
1st Support Level 59.98
2nd Support Level 59.92
3rd Support Level 59.88

See More

52-Week High 62.90
Last Price 60.05
Fibonacci 61.8% 42.80
Fibonacci 50% 36.59
Fibonacci 38.2% 30.38
52-Week Low 10.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar